-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This week, a number of large pharmaceutical companies began to announce the first quarter of 2021 financial reports and the company's latest progress.
Roche
RocheSince the outbreak of the new crown pandemic, Roche has introduced dozens of detection methods in the diagnosis of new coronaviruses.
▲The new coronavirus mutation test developed by Roche can help track the prevalence of mutant virus strains in the population (picture source: Roche official website)
▲The new coronavirus mutation test developed by Roche can help track the prevalence of mutant virus strains in the population (picture source: Roche official website)In terms of therapy development, the neutralizing antibody combination therapy casirivimab+imdevimab jointly developed by the company and Regeneron has obtained an emergency use authorization (EUA) granted by the US FDA to treat patients with mild to moderate COVID-19.
In the treatment of spinal muscular atrophy (SMA), the company's Evrysdi is the first oral therapy approved by the FDA for the treatment of SMA.
▲Evrysdi continues to improve the symptoms of SMA patients (picture source: Roche official website)
▲Evrysdi continues to improve the symptoms of SMA patients (picture source: Roche official website)In the treatment of ophthalmic diseases, the company's bispecific antibody faricimab, which targets VEGF-A and Angiopoietin-2 (Ang-2), is used in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
▲Faricimab has obtained positive results in phase 3 clinical trials for the treatment of patients with nAMD and DME (picture source: Roche official website)
▲Faricimab has obtained positive results in phase 3 clinical trials for the treatment of patients with nAMD and DME (picture source: Roche official website)Roche has launched a number of innovative therapies in recent years.
Image source: Roche official website
Image source: Roche official websiteIn addition, the Elecsys GDF-15 companion diagnostic test developed by the company was granted a breakthrough medical device designation by the FDA.
Image source: Roche official website
Image source: Roche official websiteBojian
BojianThe Alzheimer's disease treatment aducanumab jointly developed by Biogen and Eisai is currently undergoing review by the US FDA and is expected to receive the review results in June this year.
▲The progress of Bojian in the research and development of Alzheimer's disease (picture source: Bojian official website)
▲The progress of Bojian in the research and development of Alzheimer's disease (picture source: Bojian official website)Bojian reached a research and development cooperation with Sage Therapeutics last year to jointly develop a potential "first-in-class" GABAA receptor allosteric modulator zuranolone for the treatment of depression and SAGE-324 for the treatment of essential tremor.
